A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, angiomatosis, cardiovascular disorder, hereditary disease, nervous system disorder, neurocutaneous syndrome, vascular disorder, von Hippel-Lindau disease	Active, not recruiting	Phase 2	2026-04-13		NCT03401788

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	4

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Aarhus University Hospital	Aarhus	Denmark	77
Cambridge University Hospital	Cambridge	United Kingdom	4
Hospital Georges Pompidou	Paris	France	2
Huntsman Cancer Institute	Salt Lake City	United States	107
Massachusetts General Hospital	Boston	United States	1015
MD Anderson Cancer Center	Houston	United States	589
National Institutes of Health Clinical Center	Bethesda	United States	800
University of Michigan	Ann Arbor	United States	538
University of Pennsylvania Medical Center	Philadelphia	United States	9
University of Pittsburgh Medical Center	Pittsburgh	United States	63
Vanderbilt Medical Center	Nashville	United States	10